Hosted Reception Engager in Partnership with Personalis

Establishing a Robust Framework for Tumor Informed ctDNA Testing in Solid Tumors for Patient Selection, Stratification, & CDx Development

As ctDNA transitions from translational research to prospective, interventional clinical trials, biopharma companies face critical decisions in assay selection, sensitivity thresholds, and regulatory alignment. This session provides a practical roadmap for integrating ultra-sensitive, tumor-informed ctDNA platforms for solid tumors into clinical trial workflows for patient selection, response monitoring, and stratification. Join Personalis and leading biopharma partners for an interactive panel discussion on navigating the pathway from Clinical Trial Assays (CTA) to commercial Companion Diagnostics (CDx).